Two Sigma Investments LP Purchases 43,471 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Two Sigma Investments LP increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 44.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,738 shares of the company's stock after purchasing an additional 43,471 shares during the period. Two Sigma Investments LP owned 0.31% of Omnicell worth $6,310,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in shares of Omnicell during the fourth quarter valued at about $37,000. Van ECK Associates Corp increased its holdings in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Omnicell in the fourth quarter worth about $53,000. Finally, First Horizon Advisors Inc. lifted its position in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after buying an additional 355 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Up 1.5%

Omnicell stock traded up $0.44 during mid-day trading on Friday, hitting $30.27. The company's stock had a trading volume of 417,320 shares, compared to its average volume of 566,496. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a 50 day moving average of $30.51 and a 200-day moving average of $38.21. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75. The stock has a market cap of $1.42 billion, a PE ratio of 111.97, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. During the same period in the prior year, the business posted $0.03 earnings per share. The business's revenue for the quarter was up 9.5% on a year-over-year basis. On average, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Benchmark reduced their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $44.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.